Abciximab: profile and news

ROSIE Trial Shows Abciximab May Be Most Effective Combined With ... Feb 21, 2006
KISSIMMEE, FL -- February 21, 2006 -- Abciximab (ReoPro) may be more effective in combination with reteplase (Retavase) for patients with acute ischemic stroke ... - DG News

Renewal of Mural Thrombus Releases Plasma Markers and Is Involved ... Feb 28, 2006
...induce aneurysms. Fifteen rats received abciximab treatment and fifteen received irrelevant immunoglobulins. Procoagulant activity ... - Am J Pathology (subscription)

ASA: ReoPro-Retavase Duo Promising as Late Reperfusion Stroke ... Feb 20, 2006
20 - Two drugs used to treat heart attacks by different mechanisms -- ReoPro (abciximab) and Retavase (retaplase) -- may be a safe and effective combination ... - MedPage Today,

Chairman of Cleveland Clinic Department of Cardiovascular Medicine ... Feb 9, 2006
He was the first physician to administer recombinant t-PA, 2 different platelet glycoprotein IIb/IIIa inhibitors (abciximab and eptifibatide), and a new ... - International News Service,

Thrombolytic Treatment Before Stenting Linked to Increased ... Feb 14, 2006
There was no increase in mortality for patients pre-treated with glycoprotein IIb/IIIa inhibitors such as ReoPro (abciximab), Integrilin (eptifibatide), and ... - MedPage Today,

Other information

Indication
For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina

Pharmacology
Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.

Mechanism Of Action
Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa.

Drug Category
Anticoagulants; Antiplatelet Agents

Brand Names/Synonyms
ReoPro; 7E3 antibody; antiGPIIBIIIa; ReoPro (Centocor)

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Chimeric human-murine (anti CD41) 7E3 antibody.

Chemical Formula
C6462H9964N1690O2049S48 >1TXV:L ReoPro-like antibody Light Chain 1 >1TXV:H ReoPro-like antibody Heavy Chain 2 >1TXV:L ReoPro-like antibody Light Chain 2

Half Life
<10 min-30 min

Drug Type
Approved Drug

# Accession No
BIOD00041

CAS Registry Number
143653-53-6